Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 result

The IL-6-blocking monoclonal antibody ziltivekimab: its cardiovascular outcomes evidence (notably the ZEUS trial in CKD patients with elevated hsCRP), effects on inflammatory biomarkers such as hsCRP and IL-6, safety, and development status. Not for other IL-6 or anti-inflammatory agents unless directly compared with ziltivekimab.

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trial

VerifiedThe evidence, examined directly, establishes the claim.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Inflammation in atherosclerosis Atherosclerotic cardiovascular diseaseimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim or a question entirely, propose it below. A proposal is reviewed on its wording; accepted proposals are matched against the graph before they enter it.